In recent years, a great deal of research has been conducted to identify genetic poIymorp~.
many (if not all) of the genes that give rise to enzymes that metabolize environmentally relevant toxicants are polymorphic. However, the development of tools and approaches for evaluating the toxicological implications of this genetic variability has not kept pace with the identification of new genetic polymorphisms.
I
Indeed, the whole question of whether and the degree to which polymorphisms increase human variability in toxic response is not well characterized, although it has been discussed in numerous recent reviews (IngeIman-Sundberg, 200 1; Knudsen et al.. 2001; Linder and Valdes, 2001; Miller et at. 2001) . A wide range in activity between different alleles, or between a null allele and a wild type. might lead to the expectation of large differences in tissue dose arising from similar exposures. This conclusion is supported by epidemiological comparisons of cancer risk between populations with the wild-type and variant alleles that show an increased risk (or decreased risk) among populations harboring different alleles (Uematsu et al.. 1991) , and observed variability in blood or tissue levels of pharmaceuticals in patients receiving similar administered doses (Furuya et al" 1995) . On the other hand, a genetic JX>IYmorphism may have minimal or no impact on toxicity. Some genetic polymotphisms may not affect the resulting amino acid sequence (e.g.. they may be in a noncoding region of the gene. or in the coding region without altering the . encoded amino acid), and so not affect enzyme activity. Conversely, JX>lymorphisms in the regulatory region of a gene may affect gene expression or mRNA stability, and thereby modify the total level of enzyme activity in a tissue, without directly modifying the protein. Other JX>lymotphisms may affect enzyme activity, but the effect may be insignificant at environmental exJX>sure levels, perhaps because other enzymes can carry out the same reaction, or the kinetics of that enzyme are not rate limiting. Other genetic and environmental factors may also affect the enzyme level and activity. Overall, the key question for evaluating the effects of JX>lymorphisms in genes encoding metabolic enzymes is how the polymorphism affects the interindividual variability in the tissue dose of active agentT he increased recognition that there is a genetic basis for variability in xenobiotic response has led to a surge in polymorphism-related research in the toxicology field. A search of Medline in early 2002 identified over 6O,<XK> bits for "polymorphism. " of which more than 10,<XK> were published in 200 I alone. The number of identified alleles for a gene of interest may range from two (e.g., G5771, reviewed in Eaton and Bammler, 1999) to more than 70 (CYP2D6 alleles), some with more than one nucleotide change (Ingelman-Sundberg et aI.. I To whom conespondcnce should be addressed. Fax: (318) 255-2040. E-mail: rgentry@enviroocorp.com. 121 DeIcn.-ioDofpoblems AbIeIM:e of dIemicaI-specific kiJIdic ~ data UJM:ataiJlty ~ differeDCes between in vitro and in viW1 kiJIdic data AbIeIM:e of data on the relative cootribuoon of multiple enzyme systems AbIeDce of data on the allelic ~uencies for major ethnic groups numbers of low ~uency alleles UJM:ataiJlty regIrdiDg the extent of iIMhx:tiOIIfmhibiooo dIroolh coexIKJIUte
Nole. Adaped from ~ et IlL. 2(MJ2 (Haber et aI., 2002) , a list of 17 toxicologically significant chemicals was developed that are substrates for polymorphic enzymes. Infonnation on these chemicals was reviewed to identify a subset of chemicals with well-characteriled metabolic pathways, and for which allelic frequency data and phenotype data (i.e., kinetic parameters such as the VMax and KM) were available. More in-depth analyses were conducted in Phase I on four chemicals: methylene chloride (dichloromethane), warfarin, parathion, and dichloroacetic acid. Evaluation of the data for these chemicals identified several common deficiencies that increase die uncertainty in die type of analysis described here (Table I) . These are discussed more fully by Haber et al. (2002) . The present phase of die effort provides die results from two case studies, for warfarin and parathion. in which die combination of PBPK modeling and Monte Carlo analysis is used to develop a quantitative estimate of the impact of genetic polymorphisms on tissue doses, and hence internal dose metrics for risk assessment. These two case study chemicals provided a useful comparison because they are metabolized by two very different metabolic pathways, involving polymorphisms in two unrelated metabolic enzymes, with different biological implications resulting from die presence of die polymorphisms. These analyses evaluated the impact of different choices of key input data on resulting distributions of tissue doses, and downstream implications for noncancer dose-response assessment when different approoches to calculating CSAFs are used.
resulting from a given ooministered dose of the parent compound. For risk assessment scientists this question is critical in deriving "safe" or subthreshold dose estimates that are protective for a highly variable human population.
"Safe" or subthreshold doses are detennined by health agencie: § worldwide by identifying a critical effect level, such as a no observed adverse effect level (NOAEL) or benchmark dose (BMD), and dividing by uncertainty factors to account for extrapolations from the available data and for database deficiencies (Barnes and Doursoo. 1988; IPCS, 1994; Jarabek, 1994; Meek et al., 1994; U.S. EPA, 1994) . A default factor of 10 is used by most organizations to protect sensitive populations. This factor of 10 is applied to the human NOAEL (e.g., a NOAEL measured in humans or extrapolated from an animal NOAEL) and reflects the difference in sensitivities expected between the midrange of the distribution of the overall population and a sensitive individual (Dourson et aI., 1996) . As reviewed in Haber et aI. (2002) , considerable research has been performed in recent years to refine this approach beyond the use of default uncertainty factors (e.g., Baird et al., 1996; Renwick, 1993) . Recent guidance from the International Programme on Chemical Safety (IPCS, 2001) addresses the data needs for replacing default uncertainty factors with chemicalspecific adjustment factors (CSAFs). This approach breaks the intraspecies uncertainty factor into toxicokinetic and toxicodynamic components,2 each of which can be replaced by a CSAF if data are available. Depending on the data available for the chemical, the magnitude of the adjustment factor for human variability in toxicokinetics (HKAF) may be calculated based on an evaluation of human variability in such toxicokinetic factors as the area under the tissue concentration-time curve (AUC) or clearance. Physiologically based pbannacokinetic (PBPK) models can also be used to estimate HKAF based on variability in intrinsic clearance (e.g., from in vitro enzyme kinetic data; Lipscomb et al., 2002) .
The purpose of the current research effort was to develop an optimal approach for evaluating the variability in tissue dose resulting from polymorphisms in genes that encode enzymes imJ)ortant for xenobiotic metabolism. The ultimate goal is to incorporate infonnation about genetic polymorphisms into the derivation of CSAFs, and thereby enhance noncancer risk assessment by facilitating the movement from default uncertainty factor approaches to data-informed, biologically based methods. This article presents the second phase of a project designed to evaluate the toxicological significance of genetic polymorphisms in some key metabolic enzymes, by conducting case studies evaluating the extent to which the po1ymor-phisms affect tissue dose. In the first phase of the project
MATERIAlS AND METHODS
The PBPK models were initially ~ using in viw d ata from anima1s and bomans of unknown geootypes. The fined val~ f« diẽ lic p8r8meterS were dIeD compared to die metabolic p8r8meterS reported in the available in vitro studies of all known alleles. 0IK:e it was confirmed that die fined values feU within die range of die reported in vitro val~ for die diffeleftt alleles, the ~ific in vitro --and 50s were used to model the tissue dole 8DI(MIg the different JeIKItypeI. V8riability distti~ for the uea under the ~ aKVe (AUC) were ã nd examined with aDd widlOut incorporaIion of the genetic poiymorphisms in a Monte Carlo analysis. A sensitivity analysis was also conducted to detennine those paramcten whose changes most impacted estimates of inremal IkJse metrics.
2 IPCS (2001) defilleS toxicotiDetics IS "tile process of die ~ of potentially tou substu.:a by die body. !be biOUlDSf~ dIey uIxIergo, the distribution of die substances and their metabolites in die tissues, 11M! die elimination of the substances and their metabolites from the body." Toxicodynamics is defined IS "the pI'(x:es5 of in~on of chemical substances with target sites and die SUbsequeot l!:8Ctions leading to adverx effcc:ts. " GENTRY ET AI.. consisted of equal parts of (S)-and (R)-warfarin. Separate equations and parameter values were included for each enantiomer. Inhibition of (S)-warfarin metabolism by (R)-warfarin was characterized by !be addition of an inhibition tenn in !be Micbaelis-Menten equation for the rate of metabolism of (S)-warfarin: VlluU)C-;:11 /1...,., I.a:; \ ~ ,.,
where the subscripts (5') and (R) deoote (S)-warfarin and (R)-warfarin, respectively; the superscript F denotes the free (i.e., unbound) coocenb'ation; Au. is the amount in the liver; Clio is the concentration in the liver; VMax is the maximum velocity of metabolism; KM is the affinity; and KM I is the inhibition constant A similar equation was used to describe the inhibition of (R)-warfarin metabolism by (S)-warfarin. The fnM:tion of total warfarin in the plasma that is not bound was obtained by multiplying the total concentration by FFPlas, the fraction of free warfarin in the plasma, as measured by Clan et aL (1994) . Parameters describing the metabolism, oral uptake, and fraction of unbound warfarin in humans were estimated by fitting the model output to sets of data in the literature (Table 3) ; the distributions for the model paran1eters are shown in Table 4 . TIme-course data reported in Breckenridge and Orme (1973 ), Clan et aI. (1994 ), and Cboonara et aI. (1986 , were used to fit the enantiomerspecific paI'aJIleten. In the Chan et aI. (1994) and Choonara et aL (1986) studies, time-course concentrations in the plasma of either (S)-or (R)-warfarin were reported in volunteers administered a single po dose of 1.5 or 15 mg. Chan et aL (1994) also provided data on free versus bound warfarin in the Warfarin mod.L As described in the ~vious article (Haber et aL, 2002) , die stereoisomers of warfarin are metabolized by a variety of cytociuome P450 isozymes, but metabolism of (S)-warfarin is primarily by CYP2C9, and metabolism of (R)-warfarin is primarily by CYP2C19 and CYPIA2. The toxic and therapeutic effects of warfarin are due to the parent compound, and the activity of the (S)-enantiomer is approximately three times the activity of the (R)-enantiomer. Kinetic data are available for the three principal CYP2C9 alleles, CYP2C9*l, CYP2C9*2, CYP2C9*3. The protein encoded by !he wild type (CYP2C9*1) allele is the most active, and the CYP2C9*3 allele results in clinically significant changes in warfarin activity, while !he CYP2C9*2 allele appears to result in a smaller decrease in warfarin metabolism.
The warfarin model (Fig. I ) fePOIted by Luecke and Wosilait (1979) was extended by including the metabolism of both the (S)-and (R)-enantiomers of warfarin, as well as !be mutual inhibition of !be metabolism of (S)-warfarin and (R)-warfarin (Kunze et at. 1991) , and the binding of warfarin in the plasma (Chan et aI., 1994) . Tissue companments included the plasma, which included iv dose uptake and binding, !he liver, which included oral dose uptake, binding, and metabolism, plus the skin and kidney, as storage tissues. The remaining storage tissues were combined into eidJer a rapidly (other organs) or slowly (e.g., muscle or bone) perfused tissue companmenL The physiological parameters and paltition coefficients used in the warfarin model, shown in Table 2 , were obIained from the literature. Blood flows were obIained from Clewell et aL (2001) , tissue volumes were obIained from ICRP (1975) , and partition coefficients were taken from Luecke et oJ. (1994 P4rrlthioIl/panlOZOll modeL Parathion is metaoo~ via CYP3A4 and a desulfuration step to the active fonn, paraoxon (summarized in Haber et al., 2002) . Paraoxon can then exert its toxic effects by reacting with acetylcholinesterases, or it can be detoxified by the polymorphic enzyme paraoXoDase (PONI), or by a nonenzymatic ~tion with carboxylesterases. PONI is a polymorphic enzyme, with the high activity PONl homozygotes accounting for approximately 41 % of the U.S. population, the low activity homozygotes 8CCOIIDting for approximately 15% of the U.S. population, and low/high activity beterozygotes accOIIDting for approximately 45% of the U.S. population (Eckerson et at, 1983; Davies et at, 1996; Diepgen and Geldmacber-von Mallinckrodt, 1986; Haber et ai, 2002; Mueller et at, 1983; Sangha'a et al., 1998) . SiIK:e paraoxon is the active agent, low PONI activity would be expected to result in ~ sensitivity. An existing PBPK model for parathion and paraoxon developed by Gearhart et aL (1994) was used. In brief, the model describes the metabolism of parathion to paraoxon by the liver, the inhibition of acetylcholinesterase, butyrylcholinesterase, and carboxylestetase by paraoxon, and the metabolism of paraoxon by paraoxonase in the brain, liver, kidneys, rapidly perfused tissues, and the arterial and venous blood. A schematic of this model with shaded compartments indicating metabolism of paraoxon is shown in Figure 2 . The model parameters are given in Gearhart et al. (1994) and are reproduced here as the mean values ~ in Table 6 . The parathion PBPK model was a modification of a PBPK model for diisopropyl1lUorophosphate (DFP), another organophosphate whose mechanism of action is thought to be t ative of other highly toxic orga~. The DFP model was validafOO in hwnans based on dMa in humans tqIeatedIy treated ~ with DFP. Information on the kinetic differences associated with the PONI polymorphism was IX'Ovided by Davies et al. (1996) , Mueller et aL (1983), and Smolen et aL (1991) . The model p~ assumed to be affected by the polymorphism are the Michaelis-Menten metabolism parameters in the arterial and venous blood compartments, KM.., VMax.., KMv., and VMax.. (presented as scaled parameters in Table 7 ).
Mollie Carlo tIIIlJlJsis. Monte Carlo simulations were used to examine the variability in the area under the blood or plasma concentration curve (AUC) for (S)-warfarin or paraoxon following po exposure to I mg/kg warfarin or 0.033 mgikg parathion, respectively. The warfarin dose was selected because it was within the clinical range of exposures, and the parathion dose was selected because it was similar to human exposures to organophosphates reported in the available literature. For most chemicals, target tissue response is related to cumulative exposure, rather than a peak concentration; therefore, in the absence of ocher data, the AUC is a reasonable dose metric for these chemicals (IPCS, 2001) . The AUC was computed for paraoxon, the metabolite of parathion, instead of the parent compound, because paraoxon is the toxic compound. Similarly, the AUC was calculated for warfarin itself, because the parent form is the active form. As shown in Tables 4 and 6, each parameter in the PBPK models was assigned a variability distribution defined by a mean, a variance, distribution shape (log-normal or normal), and upper and lower bounds based on:!: 3 SDs (Clewell et al., 1999 (Clewell et al., ,2000 (Clewell et al., ,2001 . For the metabolic parameters affected by the polymorphisms, a separate distribution was defined for each allele. Using Latin Hypercube techniques, 1<XX> sets of values were determined by sampling from each parameter distribution. Each of the generated sets of values was then used as input to the PBPK models to estimate a corresponding distribution of the AUC.
For each chemical, multiple cases of Monte Carlo simulations were performed. A brief summary of the parameters that were varied and the distributions assigned to the metabolic parameters for each case is given in Table 8 . A more detailed discussion of each case is given in the following paragraphs.
Case I examined the potential effect of the different homozygous genotypes (i.e., the metabolic variability alone) on the distribution of the AUC if there were no ocher variability in pharmacokinetic parameters. For this case, separate simulations were performed for each homozygous genotype. The values of KM and ¥Max for homozygous individuals were randomly generated from the distributions for the allele of interest, and all other model parameters were held fixed at their mean values.
blood. Similar data were reported by Breckenridge and Orme (1973) among patients given either a po or iv dose of 0.5 mg/kg warfarin.
Although the metabolism of (R)-warfarin was considered in the PBPK model, due to the complexity of the metabolism of this enantiomer, the available information on the effect of the CYP2C9 polymorphism on it was not considered. It has ~n demonstrated that the (R)-enantiomer of warfarin is metabolized by several cytochrome P450s, but is poorly metabolized by CYP2C9. CYP2C19 has a higher affinity for (R)-warfarin, as does CYP3A4. Auempts to simulate the available time-course data on (R)-warfarin in human plasma (Choonam et al.. 1986 ) using the available kinetic parameters (KM, VMax) for CYP2C19, CYP2C9, or CYP3A4 (Kaminsky and ZJJang, 1997; Sullivan-Klose et oJ.. 1996) individually were unsuccessful, possibly due to an additional, high-affinity metabolic pathway for (R)-warfarin that has not yet been charocterized. Therefore, in contrast to the use of allele-specific experimental data for (S)-warfarin, the PBPK model for (R)-warfarin described a single metabolic pathway that represents a combination of multiple metabolic pathways, with the metabolic parameters estimated based on fitting the model to the available kinetic data.
The polymorphism in CYP2C9 and its impact on the metabolism of (S)-warfarin were examined. There are cUJIently three known human alleles of CYP2C9 for which the effects on the metabolism of (S)-warfarin have been characterized phenotypically. Information OIl the variation in the metabolism of (S)-warfarin by the enzymes encOOed by the three human alleles (CYP2C9*1. CYP2C9*2. CYP2C9*3) was provided in Haining et aL (1996) , Rettie et oJ. (1994 Rettie et oJ. ( , 1999 ; Sullivan-Klose et oJ. (1996) and Takahashi et aL. 1998a,b) . In the PBPK mOOei. the polymorphism was defined by the metabolism parameters, KM($) and VMax(S) ( Table 5 ). Since the estimates for Vmax were derived from in vitro systems not necessarily from human cell lines, this parameter was "normalized" based on the available infonnation on the general CYP content per mg procein (0.146 nmol P45<Wmg protein) in human liver microsomes (Research Diagnostics, Inc., 2001) .
Data reported by Bl~k et aL (1996) were used to validate the extended warfarin model In this study, time-<:ourse data on concentrations, AUC, and half-life of both (S)-and (R)-warfarin in the plasma were reported in male volunteers given a single po dose of 0.75 mg/lcg of a racemic mixture of warfarin. Rettie et aL. 1994 Rettie et aL. , 1999 SullivanKJose et aL, 1996; Tabbaabi et aL. 1998a,b) . All of Ibe dislrilxltiOllS defiDed by the different in vitro kinetic parameters for a given allele were sampled evenly 10 Iqxesent the full nnge of the variability aIMf uocertaiDty in these IJ8raJDetcB. This IRxo.:b was used because Ibere was 00 a priori way 10 identify (HW, set of data as peferable 10 1DOtber. based 011 study design, quality. or model fit The data used for model validation were inadequate for determining if CeItaiD ~ of p.-Imden were p'Cf~ over ~ bec8JSe Ibe relatively small sample siza for die daIa sets used for mcxIel validation may not have fully represented the variability in die population, even for die wild-type allele.
SOs were reported in only tI.ee of the five ~ used 10 cbcribe warfarin kinetics, so simulation of the warfarin metabolic patameters was IChieved through a dynamic distribution. For each simulatiOll of die metabolic parameters representing a given lKMIIOzygoos geootype, Ibe S1IXIies of dial w ere assigned equal probabilities of being chosen to define die distributioos of KM aIMf VMax. If d1e study that was chosen reported a mean and SD. the definiti<XI of die distriMItiOII was complete. If Ibe dIosen study did DO( report a SD, a SD was chosen at ruKIom from Ibe Itudies of Ibea\Je1e dial reported standard deviations.
Cme1atioo coefficients were computed as a ~ of the sensitivity of die AUC tkJIe metric 10 die nx*l pIrameIerS for each of Ibe MOllIe CarkI simulations. Pearson correlation coefficients were computed using the SAS System8.
RESULTS
F<X' Case 2, Monte Carlo simulations were perromled in <Xdcr to deteImiIIe the variability distributioo that represents a clear majority of genotypes in the popuIaIion. All of !be DM)deI parameters were v~ -S !be valof !be mdaOOIic parametersgenerated from die dislrilxltioo c)M)SeIt to ~t the "nonna)" population. For (S)-warfarin metabolism, !be most prevalent gencxype, homozygous CYP2C9* I, wu chosen to repleseot the oonnal p0p-ulation siIM:e 78.. of !be ~ poIaesseS Ibis ~.
HoweVeI", fIX' paraoxon metabolism, there is no clear WIld-type genotype. siIM:e !be homozygous high activity &enotype is present in 15.. of dte population, the bomozyp15 low activity genotype is in 40.-. of !be ~, -S 4~" of !be popuIaIion is beterozygous. To .-ovide a bencbmark population for which meaningful comparisons to a sensitive subpopulation could be made, !be "nonnaI" popuI8tioo was aI1IitlVily defined u !be high Ktivity bomozyp los !be ~ which ~ts fIX' ~ of dte popuIabOIL t ively. !be population was defined by sampling from !be distributions of the high activity -S heterozYIoos genotypes, with the probability of choosing a high activity ~ ~ to 25.. -S !be probability of cbooIina a heterozygous genotype equal to 75... This ~sponds to !be 3: I ratio between !be heterozygous -S homozygous high-activity populations. Case 3 was coIMIIM:ted to DM)deI !be v8iability in !be loCal POIMIIation. In Case 3. all par..~s were varied -S !be valfIX' !be metabolic p8rameten -randomly generated from the distributions for all genotypes, with thẽ of ~ from each disIri~ determined by !be ~aleIM:e of each genotype in !be U. S. population (Haber et aL, 2002) . The ~ of the genotypes affectiog (S)-warfarin -S plIaoxon metabolism ate shown in Table 9 . F<X' both (S)-warfario -S paraoxon, the values of the metabolic p8rameten ~ !be heterozyJOOS gellCMypcs were complied by l8II-domly selecting a val~ from each of the distributions for the tKImozygous genotypes am averaging the two values, an approach that assumes a genẽ effect. For parathion, a fourth case wu penomled to generate an AUC distribution for a sensitive subpopulation. All parameters were varied aDd the values for the metabolic parameters -raII(k!InIy generated from the disttibution for the low activity geootype to ~t !be semitive SUbpopulation.
Warfarin
Model predictions of die plasma concentration of (S)-and (R)-warfarin are compared to the data of Black et oJ. (1996) (1986) , no further adjustments to the model parameters were necessary to obtain this resulting fit to the validation data set of Black et al. (1996) . Figure 5 shows the results for Case 1 for (S)-warfarin, in which the plasma concentration over time was simulated for each of the three homozygous genotypes. Each line in the figure represents one Monte Carlo simulation. The apparent banding of the output is due to differences in the input metabolic data obtained for the same allele in different studies (fable 5). Inspection of the figures demonsb'ates that the presence of the CYP2C9*3 allele has the greatest impact on the metabolism and clearance of the (S)-enantiomer of warfarin, which is consistent with clinical observations (Aithal et aI.. 1999; Steward et al., 1997; Takahashi et al., 1998a,b; Taube et al., 2<XX» . However, CYP2C9*3 is present in less than 1 % of d1e ~Jaboo.
Approximately 12% of d1e ~Jatioo is a heterozygous genotype possessing a combination of CYP2C9* 1 and CYP2C9*2 alleles, but this heterozygous genotype would not be expected to coobibute significantly to the variability of the dose mebic among the total population since the protein encoded by CYP2C9*2 is nearly as active as the wild-type CYP2C9* I protein. The heterozygous genotype possessing a combination of CYP2C9* 1 and CYP2C9*3 alleles, however, is present in 9% of the population. Since the CYP2C9*3 protein is far less active than the wild-type, d1e presence of this heterozygous allele may increase the variability in the AUC dose mebic.
The disbibutions of the AUCs resulting from the different Monte Carlo cases were compared in order to determine the effect of the polymorphisms on the variability of tissue expo- Note. Distribution for paramet~ associated with esterase inhibition was assumed to be nonnal; for all others, it was assumed to be log-normal.
sure to (S)-warfarin. Descriptive statistics of the AUC distribution from each Monte Carlo simulation are shown in Table 10 . Figure 6 compares the distribution of the (S)-warfarin AUCs from Case 3 (i.e., varying all parameters, with the metabolic parameters sampled from the distributions for all genotypes according to the prevalence of each genotype in the U.S. population) with the AUC distribution from Case 2 (i.e., varying all parameters and generating values for the metabolic parameters from the distributions of the homozygous CYP2C9*1 genotype). In other words, Figure 6 compares the total population variability (including the polymorphisms) with the variability that would be estimated without accounting for the polymorphism. Consideration of all alleles involved in the polymorphism shifts the normal distribution to the right, demonstrating an increase in the AUC, and reflecting the contribution of the less active allelic forms. As shown in Table 10 , the polymorphism also extends the right tail of the distribution. producing a greater upper bound on the AUC and greater overall variability. For example, introducing the polymorphism increases the median AUC value from 84 to 104 mg-h/l, and increases the 95th percentile from 731 to 1170 mg-h/l. Thus, the polymorphism in CYP2C9 does increase the overall p0p-ulation variability in warfarin tissue dose. Even though the CYP2C9*3 allele occurs at a low prevalence, the difference in activity, coupled with a 9% prevalence of CYP2C9* 11 CYP2C9*3 heterozygotes, is sufficient to increase the population variability. between the AUC dose metric and the simulated input parameters were computed to determine which parameters bad the greatest impact on die AUC. Parameters demonstrating a coefficient greater than 0.1 are presented in Table 11 . The estimation of the AUC is most sensitive to changes in the parameters related to the polymorphism for CYP2C9, the VMax and KM for the metabolism of (S)-warfarin in the liver (VMaxC_S and KM_S), illusttating the importance of considering the polymorphism in reducing uncertainty in the dose metric.
Note. BIIed c-. dMa rqJOrted in Haber et aL. 2002 to paraoxon. Descriptive statistics of the AUC distribution from each Monte Carlo simulation are shown in Table 12 . The distribution of the paraoxon AUCs for the total population (Case 3) is compared with the distribution from the simulations of the high activity allele alone (Case 1) in Figure 8 and with the distribution from the simulation of the low activity allele
The results of the Monte Carlo simulations for Case I for paraoxon (Fig. 7) demonstrate bow the differences between the high and low activity alleles affect the concenb'ation of paraoxon in human blood. Each line in the figure represents one Monte Carlo simulation. These results illustrate that the presence of the high activity allele reduces circulating paraoxon concenb"ations, compared to blood concenb'ations estimated using metabolic parameters for the low activity allele. However, the range of the curves for the two alleles overlap and both allelic forms nearly completely eliminate the paraoxon within 24 h.
The disbibutions of the AUCs resulting from the different Monte Carlo cases were compared to determine the effect of the PONt polymorphism on the variability of tissue exposure 13). In Cases 2 and 3, over 100 input parameters were simulated; only the coefficients with the ten greatest magnitudes are shown. The estimation of the AUC is most sensitive to changes related to the polymorphism for paraoxonase. Two of the four parameters with the greatest impact on the arterial AUC are the VMax and KM for paraoxonase in the blood compartments, with the affinity for parathion metabolism in the liver (KMLPC and KMLEC) being the second and third most sensitive for estimating the AUC. KMLPC is the affinity for the metabolism of parathion to paraoxon and KMLEC is the affinity for the metabolism of parathion to diethyl phosphorothioic acid. It is reasonable that the paraoxon AUC is highly sensitive to these parameters because they directly influence how much paraoxon is created in the body. However, in contrast to the warfarin case study, many other parameters also had a significant impact on the AUC, reducing the impact of the polymorphism on the total variability .
DISCUSSION
In this article we demonstrate that a PBPK-Monte Carlo based approach is useful for determining the degree to which alone (Case 1). Figure 9 compares the distribution of the paraoxon AUCs for the total population (Case 3), taking into account all sources of the variability, with the distribution for the "normal" population computed by generating the values for the metabolic parameters from the distributions of the high activity homozygotes and heterozygotes (Case 2). Comparison of these two distributions reveals that, while the distribution of the AUC is shifted to the right when the low activity allele is considered in Case 3, the variability associated with the polymorphism does not greatly increase the overall variability compared to what would be expected from variability in other pharmacokinetic parameters. This result is consistent with in vivo results in laboratory animals, which suggest that the polymorphism for paraoxonase has little impact on the differences in paraoxon toxicity. Li et al. (2000) reported that Ponl gene knockout mice were not more sensitive to paraoxon than wild-type mice, suggesting that in vivo, PONI is not a major detoxification enzyme. This finding was supported by the absence of a protective effect with injections of rabbit PON1 or human PON1, and by observations of paraoxon-treated transgenic mice over-expressing the human PONI gene. However, Costa et al. (1990) found that PONI injection did protect rats against paraoxon toxicity, suggesting that the polymorphism may be significant in certain species. Correlation coefficients between the AUC dose metric and the simulated input parameters were computed to determine which parameters had the greatest impact on the AUC (Table polymorphisms influence human variability in tissue dose, and for integrating polymorphism data into human health risk assessments. This approach increases the degree to which genetic polymorphisms can be taken into account in assigning uncertainty factor values for variability in human sensitivity-a critical decision point in noncancer risk assessment Traditionally, uncertainty factors in noncancer risk assessment have considered both interspecies differences and intraspecies variability. Each of these factors is comprised of two components: phannacokinetics and pharmacodynamics. In recent years, there has been an attempt to develop methodology for the incorporation of more chemical-specific data into the consideration of these factors. As discussed previously, one example of this type of methodology has been developed under the IPCS initiative on the Hannonization of Approaches to the Assessment of Risk from Exposure to Chemicals (Fig. 10) .
Based on the IPCS guidance (2001), the current results on human variability in tissue dose fOl" warfarin and parathion could be used to estimate a Chemical Specific Adjustment Factor (CSAF) to replace the standard adjustment factor of 3.2 for intrahuman variability in phannacokinetics (HKAP), and thus represent a step forward in the goal of incorporating the best available science into the risk assessment process. Sufficient data are available for both warfarin and parathion for the development of CSAFs, based on the criteria developed by IPCS (2001) . The active chemical form has been identified (warfarin and paraoxon). For both chemicals, AUC in blood or plasma was considered an appropriate toxicokinetic parameter, and an appropriate PBPK model was available. Kinetic data from the oral route (the route of interest) were used to validate the models developed using in vitro kinetic parameters. Information on allelic frequencies in the general U.S. population was used, improving the degree to which the data describe the total population variability. Finally, the major metabolizing tissues for both warfarin and paraoxon are tissues other than the target tissue, so the variability estimated is clearly toxicokinetic variability, not toxicodynamic variability.
The IPCS (2001) CSAF guidelines recommend that HKAP be calculated as the ratio between "given percentiles (such as 95th, 97 .5th, and 99th) and the central tendency for the whole population. Alternatively, where there are sensitive subgroups, this ratio is the upper percentile for the sensitive subgroup and the central tendency for the whole population." The guidance does not specify whether the median or mean should be used as sampled from die distributions fIX aD lenotypes according to die prevaIeuce of e8Cb genotype in die U.S. population). a measure of central tendency. Because the IPCS guidance allows different options for calculation of CSAFs, the implications of several different options were considered in our analysis. Specifically, CSAFs were computed as the ratio of the 95th or 99th percentile of the AUC distributions to the mean or median of the AUC distributions. The implications of using the 95th percentile of the total population versus the 95th percentile of the sensitive population were also explored. Table 14 shows CSAFs calculated for warfarin by applying the IPCS methodology to the results in Table 10 . No CSAFs are shown for Case 1 (varying only the metabolism parameters defining the polymorphism and considering only homozygotes), because this case does not consider how variability in other pharmacokinetic parameters affects the AUC. (These considerations were addressed in the full analysis conducted for Case 3.) When all of the parameters (including those for the polymorphism) were allowed to vary (Case 3), the calculated CSAFs ranged from 3.8 to 26. Using the 95th percentile to represent the sensitive individual and the mean to represent the average individual, the warfarin CSAF of 3.8 is approximately equal to the default factor of 100.5 (3.2) for phannacokinetic variability. When the average individual is represented by the median instead of the mean, the calculated CSAF increases to 11. Since the population distribution of S-warfarin tissue dose is highly skewed, rather than being symmetric about the mean (Fig. 6) , the median is a more appropriate choice in this case, because it is less sensitive to extreme values.
CSAFs for Case 2 (excluding the polymorphism) were calculated to provide a point of comparison, in order to evaluate the impact of the polymorphism on the CSAFs. The CSAF for warfarin calculated as the 95th percentile/mean for Case 2 is very similar to that calculated for Case 3, but the other Case 2 CSAFs (P95/median, P99/mean, P99/median) were clearly smaller than the corresponding Case 3 values, reflecting the decreased variability in the absence of the polymorphism. Use of the 99th percentile instead of the 95th percentile approximately doubled the calculated CSAF for warfarin for bod1 Case 2 and Case 3. Table 14 also shows CSAFs calculated for parathion by applying the IPCS methodology to the results in Table 12 .
Comparison of the results from Cases I and 3 show that consideration of all sources of variability actually reduced the CSAF compared to consideration only of variability due to the polymorphism. This is because the variability of the whole population is considered in Case 3, where the variability of only the high activity or low activity genotype is considered in Case I. All of the CSAFs calculated for parathion were comparable to 01" smaller than the default of 3.2 for pbarlOacokinetic variability, reflecting the relatively tight distribution of the paraoxon AUC (Fig. 9) . The calculated CSAFs varied by Jess than 15% when the median was used instead of the mean. consistent with the near-normality of the distribution. Similarly, use of the 99th ~ntile instead of the 95th percentile increased the CSAF by only 33%. The parathion results were also used to test the implications of using the 95th ~ntile of the total population versus using the 95th ~ntile of the sensitive population (Fig. 11 ). For the latter approach, the nonnal population was defined as the high activity homozygates plus the heterozygotes, accounting for ro% of the p0p-ulation; descriptive statistics for this group are shown as Case 2 in Table 12 .1be sensitive population was reJXesented by the low activity homozygotes, as shown in Case 4 in Table 12 . The CSAFs for parathion computed using the 95th percentile of the sensitive population are approximately 50% higher than those calculated using the 95th percentile of the total population. We also compared the CSAFs calculated using this PBPKMonte Carlo approach with ones that would be calculated by naively comparing the intrinsic clearance for the different alleles (Tables 7 and 8 ). Comparing the intrinsic clearance of warfarin obtained with the CYP2C9*1 and CYP2C9*3 pr0-teins in a given report (to avoid interlaboratory variability) results in CSAFs ranging from 5.8 (for Sullivan-Klose et ai, 1996) to 26 (for Haining et ai, 1996) . H these values are default of 3.2 may underestimate the "correct" adjustment factor by a factor of approximately 3.4.
Issues, Uncertainties, and Implications for Study Design
The analysis presented here demonstrates that PBPK modeling can be combined with Monte Carlo analyses to evaluate total variability in tissue dose and implications of different definitions of CSAFs. Due to the large number of uncertainties in this analysis, however, we consider this article to be more a demonstration of an approach, rather than deriving definitive CSAFs for the development of RfDs for these chemicals.
A primary source of uncertainty for the warfarin analysis was the surprising degree of variability in the data reported for a given isoform using different expression systems (Table 5) . Because no clear basis could be identified for choosing one set of kinetic values over another, all of the data were used together, as an indication of the uncertainty regarding the true enzyme kinetics. This approach, however, meant that the distribution of VMax and KM included inter-(and intra-) laboratory reproducibility as one component of the uncertainty. Information on which expression systems are most representative of in vivo enzyme kinetics could help to inform the choice of expression system, both for laboratory scientists, and for risk assessors/modelers conducting similar exercises in the future. Kinetic data from enzymes in in vitro expression systems may also be distorted by differences in the degree of expression of the enzyme of interest. For example, in the available literature the VMax data for warfarin are expressed in terms of activity per nmol P450 (Haber et al., 2002) . Because the activity was not normalized to the amount of CYP2C9, differences between expression systems in the amount of CYP2C9 protein present compared to the CSAFs presented in Table 14 , they are similar in magnitude. However, if a similar comparison is conducted for parathion (Table 8) , the ratio of high activity to low activity intrinsic clearance is approximately 7, which is roughly a factor of 3 greater than the CSAF of 2.1 (P95/mean, Case 3). The danger in calculating CSAFs directly from the in vitro data is that it ignores the interplay of the polymorphism with other pharrnacokinetic factors. For example, if metabolism is flowlimited, variation in enzyme activity may have minimal effect on tissue dose (Clewell et al.. 2001; Lipscomb et al.. 2002) . Due to the lack of these considerations, using comparisons of intrinsic clearance may not adequately describe the in vivo variability resulting from polymorphisms. Therefore, the r0-bust analysis provided using a PBPK-Monte Carlo approach is more appropriate for developing CSAFs.
In our analysis, warfarin and parathion provide two rather different case studies for evaluating the implications of various choices made in calculating CSAFs. For warfarin, there is significant in vivo variability in toxicokinetics (primarily due to the CYP2C9*3 allele), and the calculated CSAF was markedly different with the use of mean versus median, or 95th versus 99th percentile. By contrast, total human kinetic variability is rather small for the critical metabolite of parathion, and the paraoxonase polymorphism appears to contribute minimally to this variability; alternative definitions of the CSAF for parathion resulted in only minor quantitative differences. Based on these analyses, the default CSAF of 3.2 for human variability in toxicokinetics is adequate or slightly overprotective for parathion. By contrast, a subfactor of 3.2 is not adequately protective for human variability in S-warfarin toxicokinetics. Focusing on the ratio of the 95th percentile and the median, the HKup. human variability kinetic uncertainty factor. CP. composite factor. OJemical-specific d8ta CID be used to replace . def8ult uIK:ertaiDty fM:tor (UF) by an IdjusbneDt fM:tor (AI"). In die absence of appropriate data. the subdivision of the I~fold factors coU..-es b8ck 10 the 1000foid f~.
was not available for several of the in vitro studies providing metabolic parameters. As described in the Methods section, the SOs from other in vitro studies were applied randomly to the studies for which no SDs were available. This approach could be avoided if experimental reports of enzyme kinetics include a measure of variability.
Several assumptions and simplifications were also needed for the warfarin analysis. The enzymatic activity of the heterozygotes was assumed to be the average of the activity of the homozygotes for each of the two alleles represented in the heterozygote, under an assumption of a gene dosage effect. The analysis was conducted only for (S)-warfarin, the more active enantiomer; good model fit could not be obtained for the PBPK model for (R)-warfarin using available in vitro activities. Fimay account for some or all of the differences among expression systems. Using an antibody specific to CYP2C9 (e.g., a monoclonal antibody), and normalizing the enzyme activity to the amount of CYP2C9 protein present would provide a more uniform measure of enzyme activity. Kinetic data developed directly from human tissues with known genotypes provides the ideal form of input data for the sort of analysis conducted here, in which enzyme data (VMax and KM) are used as a parameter in the PBPK-Monte Carlo analysis. In the absence of human tissue data, enzyme kinetics detennined for the allelic form of interest can be used. The data should be collected using the substtate of concern. and normalized to the amount of the enzyme that is present. However, further departures from the ideal data set increase the uncertainty in the use of kinetic data on polymorphisms to define CSAFs for risk assessment.
An additional source of uncertainty in the warfarin analysis was that information on variability (SD or similar measure) nally, only variability in the major metabolic pathway for (S)-warfarin, via CYP2C9, was considered; metabolism by other CYPs was not included in the model. There are also several uncertainties in the parathion analysis, particularly with regard to characterization of its metabolism. Metabolism of paraoxon by PONI was included in the PBPK model, but variability in the generation of paraoxon was based on observed variability in kinetic parameters for other chemicals (Clewell et al.. 1999 (Clewell et al.. , 2(xx), 2001 . Insufficient data were available to quantitatively include data on polymorphism of CYP3A4 in the analysis of variability in the generation of paraoxon. In addition, genotype does not fully account for the variability in PONI metabolic capacity. Clearance among individuals with the same low metabolism genotype ranged over 13-fold, at least partially due to differences in protein levels (Furlong et aI., 1993) . These differences in protein levels could not be accounted for in the current analysis, which rely on in vitro enzyme kinetic data to represent the impact of the paN] polymorphism. This resulting uncertainty emphasizes the value of kinetic data for human tissues as an ideal input for the PBPK modeling. Nonetheless, we believe that the kinetic parameters used based on the in vitro data do adequately represent the situation in vivo (although maybe not the full in vivo variability), based on our ability to replicate in vivo data.
Implications for Future Work
This article, together with our previous companion article (Haber et aL, 2002) , identifies the minimal data needed to conduct a chemical-specific analysis of the effect of polymorphism on tissue dose. The minimal data needed are summarized in Table 15 . The minimal data identified are very similar to the criteria initially identified in choosing the case studies for this analysis (Haber et aL, 2002) . The primary difference is that we found that chemical-specific phenotype data are necessary; phenotype data using other related substrates is not sufficient. Our initial hope in beginning this analysis was that we would be able to reach generalized conclusions regarding the effects of a specific polymorphism for a class of related chemicals. However, we found that there are marked differences in the effects of a polymorphism among related chemicals. For example, Li et aL (2CXX» found that the two human plasma PONII92 isoforms differed by a factor of approximately 9-fold in the inbinsic clearance (VMaxKM) of paraoxon, but the intrinsic clearance of the two forms was nearly identical for diazoxon hydrolysis (although VMax and KM individually differed by approximately 3-fold). For hydrolysis of chlorpyrifos oxon, the inbinsic clearance of the two polymorphic forms differed by a factor of about 1.7. These data show that a given amino acid change can have very different quantitative effects on the kinetics of an enzyme towards closely-related substrates.
Combining PBPK modeling and Monte Carlo analysis provides a powerful (although labor-intensive) approach for quantitatively characterizing the effects of polymorphisms on human variability in tissue dose. Because this is a labor-intensive process, key questions need to be addressed in considering this approach. These key questions could be incorporated into the future development of an overall decision framework for integrating polymorphism data into risk assessments.
The first level of questions in this framework would address whether the approach is likely to impact estimates of human variability. Has a polymorphism(s) been identified in a key metabolic enzyme for the chemical of interest? Are there other (unquantified) major conbibutors to variability? Our case study of parathion highlights this latter point, where other sources of variability likely minimized the impact of the polymorphism on variability in tissue dose. As another example, using an analysis of this type to address variability for a chemical metabolized by CYP2El would not be fruitful (even assuming that a polymorphism affecting CYP2El activity were known), unless information was included on the large degree of environmentally related variability in CYP2El activity. Identification of the active agent (e.g., parent vs. metabolite) is also desirable at this stage. It is possible, however, to conduct the analysis in the absence of such knowledge. In that case, one would need to calculate the effect of the polymorphism on both the tissue dose of the parent and of the metabolite, recognizing that the polymorphism may increase or decrease toxicity. Determination of the active agent would be needed before the results of such an analysis were incorporated into a risk assessment, such as for calculation of a CSAF.
The second level of questions might address whether the available input data are adequate. These questions address whether the criteria listed in Table 15 are met, with particular attention to chemical-specific phenotype data. If the criteria listed in Table 15 are met, the approach described in this article can be used. If the criteria are not met, additional data would need to be generated. or a PBPK model developed, in order to apply this approach. As a long-term goal, it may become possible to take the lessons learned from this current analysis, as well as future analyses presented in the literature, to develop more fully a general decision framework for incorporating polymorphism data into risk assessments. This would be a useful tool as risk assessment scientists will need to address the impact of a continually growing list of genetic polymorphisms in conducting chemical risk assessments. 
